EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared Scancell to run a phase 2 trial of SCIB1 in combination with Keytruda. Scancell’s effort to get the study underway was previously held up by the FDA’s request for more information. Statement 

> Valneva entered into an $85 million (€77 million) financing agreement with Deerfield and OrbiMed. The financing  comes ahead of a planned listing on Nasdaq. Release

> Valo Therapeutics raised money to support production of its lead oncolytic adenovirus program in anticipation of entering the clinic next year. The Anglo-Finnish biotech plans to close a series A round later this year. Statement 

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

> Freeline appointed Theresa Heggie as its CEO. Heggie is leaving Alnylam to take up the position. Release 

> Autolus Therapeutics presented data on one of its CAR-T candidates, AUTO3. Four of the seven diffuse large B-cell lymphoma patients who received a certain dose of AUTO3 in combination with Keytruda had complete responses. Statement I Presentation (PDF)

> Avacta teamed up with AffyXell Therapeutics to develop cell and gene therapies. Release 

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.